AKBA
Price
$2.15
Change
+$0.01 (+0.47%)
Updated
Feb 5, 01:02 PM (EDT)
Capitalization
462.54M
35 days until earnings call
ANNX
Price
$3.71
Change
+$0.02 (+0.54%)
Updated
Feb 5, 01:03 PM (EDT)
Capitalization
393.33M
43 days until earnings call
Ad is loading...

AKBA vs ANNX

Header iconAKBA vs ANNX Comparison
Open Charts AKBA vs ANNXBanner chart's image
Akebia Therapeutics
Price$2.15
Change+$0.01 (+0.47%)
Volume$14.06K
Capitalization462.54M
Annexon
Price$3.71
Change+$0.02 (+0.54%)
Volume$300
Capitalization393.33M
AKBA vs ANNX Comparison Chart
Loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ANNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKBA vs. ANNX commentary
Feb 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a Hold and ANNX is a Buy.

Ad is loading...
COMPARISON
Comparison
Feb 05, 2025
Stock price -- (AKBA: $2.14 vs. ANNX: $3.69)
Brand notoriety: AKBA and ANNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBA: 58% vs. ANNX: 72%
Market capitalization -- AKBA: $462.54M vs. ANNX: $393.33M
AKBA [@Biotechnology] is valued at $462.54M. ANNX’s [@Biotechnology] market capitalization is $393.33M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.44B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whileANNX’s FA Score has 1 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • ANNX’s FA Score: 1 green, 4 red.
According to our system of comparison, both AKBA and ANNX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 2 TA indicator(s) are bullish while ANNX’s TA Score has 4 bullish TA indicator(s).

  • AKBA’s TA Score: 2 bullish, 7 bearish.
  • ANNX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ANNX is a better buy in the short-term than AKBA.

Price Growth

AKBA (@Biotechnology) experienced а -6.55% price change this week, while ANNX (@Biotechnology) price change was -10.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.22%. For the same industry, the average monthly price growth was +0.86%, and the average quarterly price growth was +14.14%.

Reported Earning Dates

AKBA is expected to report earnings on May 12, 2025.

ANNX is expected to report earnings on May 19, 2025.

Industries' Descriptions

@Biotechnology (+5.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBA($463M) has a higher market cap than ANNX($393M). AKBA YTD gains are higher at: 12.632 vs. ANNX (-28.070). AKBA has higher annual earnings (EBITDA): 4.3M vs. ANNX (-129.45M). ANNX has more cash in the bank: 340M vs. AKBA (34M). ANNX has less debt than AKBA: ANNX (29.6M) vs AKBA (48.6M). AKBA has higher revenues than ANNX: AKBA (170M) vs ANNX (0).
AKBAANNXAKBA / ANNX
Capitalization463M393M118%
EBITDA4.3M-129.45M-3%
Gain YTD12.632-28.070-45%
P/E RatioN/AN/A-
Revenue170M0-
Total Cash34M340M10%
Total Debt48.6M29.6M164%
FUNDAMENTALS RATINGS
AKBA: Fundamental Ratings
AKBA
OUTLOOK RATING
1..100
78
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
38
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AKBAANNX
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
N/A
Bullish Trend 8 days ago
83%
Declines
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ANNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GMXAX16.370.09
+0.55%
Nationwide Mid Cap Market Idx A
JSGCX24.90N/A
N/A
JHancock U.S. Growth C
SJGIX31.37N/A
N/A
Steward Large Cap Growth I
TGFRX48.53N/A
N/A
Tanaka Growth
AEIUX8.64N/A
N/A
American Century Equity Income R5

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with ABOS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+0.94%
ABOS - AKBA
43%
Loosely correlated
-1.33%
KOD - AKBA
40%
Loosely correlated
-0.86%
FBIO - AKBA
40%
Loosely correlated
+0.82%
BEAM - AKBA
39%
Loosely correlated
+0.63%
ABCL - AKBA
39%
Loosely correlated
+4.22%
More

ANNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANNX has been loosely correlated with DNTH. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ANNX jumps, then DNTH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANNX
1D Price
Change %
ANNX100%
+4.83%
DNTH - ANNX
41%
Loosely correlated
+1.00%
FULC - ANNX
40%
Loosely correlated
+0.26%
TCRX - ANNX
37%
Loosely correlated
N/A
AKBA - ANNX
36%
Loosely correlated
+0.94%
ERAS - ANNX
36%
Loosely correlated
+1.14%
More